Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adicet Bio, Inc. (ACET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Adicet uses these filings to report on its allogeneic gamma delta CAR T cell programs in autoimmune diseases and cancer, capital raising transactions, and key corporate actions.
Investors can review Form 8-K current reports in which Adicet describes material events such as preliminary Phase 1 data for ADI-001/prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus, updates on enrollment across additional autoimmune indications, strategic pipeline prioritization and discontinuation of ADI-270, and development plans for the ADI-212 solid tumor program. Other 8-K filings cover registered direct offerings of common stock and pre-funded warrants, Nasdaq bid price notices and market transfers, and workforce reduction decisions.
The company’s proxy materials, such as the definitive proxy statement on Schedule 14A for a special meeting of stockholders, outline proposals including amendments to the certificate of incorporation to effect a reverse stock split within a specified range and potential adjournments to solicit additional proxies. These documents detail how stockholders can vote, participate in virtual meetings, and understand the rationale for capital structure changes.
On Stock Titan, ACET filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly identify topics such as clinical data disclosures, financing terms, reverse stock split mechanics, and listing compliance discussions. Users can also locate quarterly and annual reports when filed (Forms 10-Q and 10-K), as well as any Form 4 insider transaction reports, to build a more complete picture of Adicet Bio’s financial condition, governance, and progress in advancing its gamma delta CAR T pipeline.
Adicet Bio, Inc. received a Schedule 13G reporting that investment manager Franklin Advisers, Inc., a subsidiary of Franklin Resources, beneficially owns 626,571 shares of Adicet Bio common stock, representing 6.5% of the outstanding class as of 12/31/2025.
Franklin Advisers is reported to have sole voting and sole dispositive power over these shares. The shares are held in client accounts of Franklin’s investment management subsidiaries, whose clients have the right to receive dividends and sale proceeds. Franklin Resources and its principal shareholders may be deemed beneficial owners under SEC rules but disclaim pecuniary interest and state the holdings are in the ordinary course of business, not to influence control of Adicet Bio.
Adicet Bio's Chief Scientific Officer, Aftab Blake, reported a routine share withholding related to equity compensation. On January 24, 2026, 535 shares of common stock were withheld at $8.44 per share to cover tax obligations arising from the vesting of restricted stock units, and this did not involve an open-market sale. Following this withholding, Blake directly beneficially owned 2,981 shares of Adicet Bio common stock. The reported holdings also reflect a 1-for-16 reverse stock split that Adicet Bio effected on December 30, 2025.
Adicet Bio, Inc.’s Chief Technology Officer Don Healey reported an administrative share adjustment related to equity compensation. On 01/24/2026, 535 shares of common stock were withheld by the company at
Adicet Bio President & CEO Schor Chen reported a routine share withholding related to equity compensation. On January 24, 2026, the company withheld 1,755 shares of common stock at $8.44 per share to cover tax obligations from vesting restricted stock units, which is not a market sale.
After this transaction, Chen reports 6,820 common shares held directly. In addition, 2,716 shares are held indirectly through The I. Schor IRRV Trust and 3,339 shares are held indirectly through The C. Schor IRRV Trust, both irrevocable family trusts with independent trustees. The holdings reflect a previously effected 1-for-16 reverse stock split.
Adicet Bio Chief Financial Officer Brian Nicholas Harvey reported a routine tax withholding related to restricted stock units. On January 24, 2026, 546 shares of Adicet Bio common stock were withheld at $8.44 per share to cover tax obligations upon RSU vesting, and this did not involve an open-market sale. After this withholding and giving effect to a 1-for-16 reverse stock split completed on December 30, 2025, he beneficially owned 5,145 common shares directly.
Adicet Bio reported clinical and regulatory progress for its cell therapy programs. Enrollment in its Phase 1 trial of prulacabtagene leucel (prula-cel, formerly ADI-001) in autoimmune diseases has doubled to over 20 patients as of December 31, 2025. The company has also reached alignment with the U.S. Food and Drug Administration to allow patients with lupus nephritis and systemic lupus erythematosus to be dosed with prula-cel in the outpatient setting in ongoing and future trials. Adicet plans to request a meeting with the FDA in the second quarter of 2026 to inform potential Phase 2 pivotal trial design for prula-cel and expects to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in the first half of 2026.
Adicet Bio, Inc. (ACET) has called a virtual special meeting of stockholders on December 19, 2025 to vote on a reverse stock split and a possible adjournment of the meeting. The company is asking investors to approve an amendment to its certificate of incorporation that would allow the board to combine existing common shares into a smaller number of shares at a ratio between one-for-five and one-for-thirty, with the exact ratio set later by the board. As of November 14, 2025, Adicet Bio had 153,255,581 common shares outstanding and its stock closed at $0.66 per share, below Nasdaq’s $1.00 minimum bid requirement. The board explains that the reverse split is intended to help regain compliance with Nasdaq listing rules and potentially broaden investor interest. A second proposal would allow the meeting to be adjourned to solicit additional proxies if there are not enough votes to approve the reverse split.
Adicet Bio (ACET) called a virtual special meeting to seek stockholder approval to amend its charter to effect a reverse stock split within a range of one-for-five to one-for-thirty, with the exact ratio set by the board in its sole discretion. The company says the split is intended to help regain compliance with Nasdaq’s
The meeting is scheduled for December 19, 2025 at 8:00 a.m. ET, and will be held online at www.virtualshareholdermeeting.com/ACET2025SM. Only holders of record as of November 14, 2025 may vote. A separate proposal would allow adjournment to solicit additional proxies if needed.
If implemented, fractional shares will be paid in cash, outstanding share counts will be reduced by the chosen ratio, and authorized shares will remain at 300,000,000, increasing the proportion of authorized but unissued shares. The board may implement the split within one year of approval or abandon it at its discretion.
Adicet Bio (ACET) reported Q3 2025 results with a net loss of
Liquidity remained the key focus. As of September 30, 2025, cash and cash equivalents were
In October 2025, the company completed an underwritten registered direct offering of 70,001,000 shares at
Adicet Bio (ACET) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025.
The detailed results are provided in a press release furnished as Exhibit 99.1. The company specifies that the information in this report and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference except as specifically stated.